Featured

Manitobans can now purchase a Manitoba Motorcycle Ride for Dad specialty licence plate, with each sale supporting the fight against prostate cancer. Released by Manitoba Public Insurance (MPI) on Monday, the $70 licence plate is available at any Autopac agent—with $30 from each plate going to the Manitoba Prostate Cancer Support Group.

As of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk of metastasis (high-risk BCR).i This decision means XTANDI is now publicly reimbursed in Ontario for all of its approved prostate cancer indications.

CCSN hosted a virtual prostate cancer patient focus group to gain insights on the experiences of individuals receiving treatment for prostate cancer, focusing on management approaches, side effects, and overall impact on quality of life. It was also discussed how we could identify strategies to optimize support for those living with prostate cancer.

Effective February 1, 2025, Nova Scotia is publicly funding Pluvicto, a targeted radioligand therapy. -Published on February 3rd 2025

Scientists have developed a spit test that could “turn the tide” on prostate cancer worldwide by spotting the disease earlier, detecting where men are at high risk and sparing others unnecessary treatment.

Not only do participants enjoy participating in great physical activity, but the study also showed the positive impact on men’s psychosocial wellbeing as being even more important. And to this I personally attest.